Jan 6, 2022 Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event
Sep 17, 2021 Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares
Sep 14, 2021 Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock
